Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2007. The report details a specific corporate action regarding a share repurchase authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements:
- Shares Purchased: 650,000 Ordinary shares.
- Purchase Price: 1,389.22 pence per share.
- Treasury Shares Held: 241,382,678 shares (post-transaction).
- Shares in Issue: 5,752,035,381 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the open market purchase of 650,000 shares. These shares are intended to be held in Treasury. The filing does not disclose changes in operating performance or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (241,382,678) against subsequent filings.
- Confirm the total voting rights denominator (5,752,035,381) for disclosure threshold calculations under FSA rules.
- Check the authorization status of the share buyback program relative to the May 17, 2006 shareholder approval.